Evan Dellon is a Gastroenterology physician affiliated with University of North Carolina at Chapel Hill. OpenAlex indexes 1,312 publications with 38,658 citations (h-index 92); ClinicalTrials.gov lists 12 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Gastroenterology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Cb # 7080
Bioinformatics Building, 130 Mason Farm Road
Chapel Hill, NC 275997080
Telephone
919-966-2511Registry record last updated 21 Nov 2012.
Clinical trials
- A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
Sponsor: University of North Carolina, Chapel Hill
- Dupilumab for Eosinophilic Esophagitis With Severe Strictures
Sponsor: University of North Carolina, Chapel Hill
- 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
Sponsor: Ellodi Pharmaceuticals, LP
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year20256 payments$21,936openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20255 payments$18,477openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year20259 payments$16,434openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
9 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- A Trial of Upadacitinib for Non-responsive Eosinophilic esophagitis (ATUNE)
Univ of North Carolina Chapel Hill
FY2026$781,365R01DK146043 - Porcine Related apprOach to Multidisciplinary cOllaborative Translational ModEl Research (PROMOTER)
Univ of North Carolina Chapel Hill
FY2026$770,559RC2TR005123
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis
The American Journal of Gastroenterology
2025 - One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial
The Lancet. Gastroenterology & hepatology
2023 - Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
New England Journal of Medicine
2022 - International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature
Clinical Gastroenterology and Hepatology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Norman Sharpless, MD
University of North Carolina at Chapel Hill
Douglas Drossman, MD
University of North Carolina at Chapel Hill
Charles Rice, MD
The Rockefeller University
Kris Kowdley, MD
Washington State University
Eamonn Quigley, MD
Houston Methodist Hospital and Academic Institute
Patrick Kamath, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”